-
Dec 30, 2024 | 
alzres.biomedcentral.com | Maxime Van Egroo |Elise Beckers |Nicholas Ashton |Kaj Blennow |Henrik Zetterberg
ReferencesVan Egroo M, Narbutas J, Chylinski D, Villar González P, Maquet P, Salmon E, et al. Sleep–wake regulation and the hallmarks of the pathogenesis of Alzheimer’s disease. Sleep. 2019;42:1–13. Google Scholar Rigat L, Ouk K, Kramer A, Priller J. Dysfunction of circadian and sleep rhythms in the early stages of Alzheimer’s disease. Acta Physiol. 2023;238:1–13. Google Scholar Winer JR, Morehouse A, Fenton L, Harrison TM, Ayangma L, Reed M, et al.
-
Dec 23, 2024 | 
alzres.biomedcentral.com | Georgette Argiris |Muge Akinci |Cleofé Peña-Gómez |Eleni Palpatzis |Marina García-Prat |Mahnaz Shekari | +8 more
ReferencesJack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62. Article PubMed Google Scholar Milà-Alomà M, Suárez-Calvet M, Molinuevo JL. Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer’s disease. Ther Adv Neurol Disord. 2019;18(12):1756286419888819.
-
Nov 17, 2024 | 
nature.com | Stephan A. Kaeser |Christian la Fougère |Jonathan Voglein |Johannes Levin |Nick Fox |Henrik Zetterberg | +16 more
AbstractDisease-modifying therapies for Alzheimer’s disease (AD) are likely to be most beneficial when initiated in the presymptomatic phase. To track the benefit of such interventions, fluid biomarkers are of great importance, with neurofilament light chain protein (NfL) showing promise for monitoring neurodegeneration and predicting cognitive outcomes.
-
Nov 17, 2024 | nature.com | Stephan A. Kaeser |Christian la Fougère |Jonathan Voglein |Johannes Levin |Nick Fox |Henrik Zetterberg | +16 more
AbstractDisease-modifying therapies for Alzheimer’s disease (AD) are likely to be most beneficial when initiated in the presymptomatic phase. To track the benefit of such interventions, fluid biomarkers are of great importance, with neurofilament light chain protein (NfL) showing promise for monitoring neurodegeneration and predicting cognitive outcomes.
-
Nov 14, 2024 | 
bpspsychub.onlinelibrary.wiley.com | Joel Simrén |Nicholas Ashton |Marc Suárez-Calvet |Henrik Zetterberg
Recent developments in fluid and imaging biomarkers that reflect the key pathological hallmarks of Alzheimer's disease (AD)—deposits of extracellular amyloid-β (Aβ) and intracellular tau proteins—have transformed the perception of the disease in living individuals from a clinical syndrome to a biological continuum that begins prior to the onset of symptoms (Scheltens et al., 2021).
-
Nov 11, 2024 | 
nhl.com | Henrik Zetterberg
Longtime Red Wings teammate lauded for strength, skill as 2-way dynamo, half of 'Eurotwins' By Henrik Zetterberg / Special to NHL.com November 11, 2024
Henrik Zetterberg joined the Detroit Red Wings in 2002-03, one season after Pavel Datsyuk. They played together for 13 seasons, making the Stanley Cup Playoffs each season and winning the Cup in 2008.
-
Oct 28, 2024 | 
nature.com | Stacey L. Kigar |Leonidas Chouliaras |Noah S. Shapiro |George Savulich |Kaj Blennow |Henrik Zetterberg | +2 more
AbstractThe innate immune system plays an integral role in the progression of many neurodegenerative diseases. In addition to central innate immune cells (e.g., microglia), peripheral innate immune cells (e.g., blood monocytes, natural killer cells, and dendritic cells) may also differ in these conditions. However, the characterization of peripheral innate immune cell types across different neurodegenerative diseases remains incomplete.
-
Oct 16, 2024 | 
biorxiv.org | Katharina Waury |Hlin Kvartsberg |Henrik Zetterberg |Kaj Blennow
AbstractAntibodies are indispensable in laboratory and clinical applications due to their high specificity and affinity for protein antigens. However, selecting the right protein fragments as immunogens for antibody production remains challenging. Leveraging the Human Protein Atlas, this study systematically evaluates immunogen properties aiming to identify key factors that influence their suitability.
-
Oct 11, 2024 | 
biorxiv.org | Katharina Waury |Hlin Kvartsberg |Henrik Zetterberg |Kaj Blennow
AbstractAntibodies are indispensable in laboratory and clinical applications due to their high specificity and affinity for protein antigens. However, selecting the right protein fragments as immunogens for antibody production remains challenging. Leveraging the Human Protein Atlas, this study systematically evaluates immunogen properties aiming to identify key factors that influence their suitability.
-
Oct 8, 2024 | 
nature.com | Clara Vila-Castelar |Eleni Palpatzis |Kaj Blennow |Henrik Zetterberg |Juan Domingo Gispert |Marc Suárez-Calvet | +2 more
AbstractGlial reactivity may contribute to sex/gender differences in Alzheimer’s disease (AD) pathophysiology. Here, we investigated the differential effect of cerebrospinal fluid (CSF) glial markers on AD pathology and neurodegeneration by sex/gender among cognitively unimpaired older adults at increased risk of developing AD.
